“This is for sure going to work,” Surge Biswas, PhD, CEO of Nabla Bio, told me when asked to weigh in on the future outlook of de novo antibody design, or designing antibodies not found in nature.

In recent years, a hand full of AI startup companies that managed to utilize AI/ML to discover novel targets and/or design therapeutics reached human clinical trials and received massive media ...

Nxera will hold an exclusive licence for the antibody assets globally, granting full rights for their development and commercialisation. The initial project will focus on antibodies’ design with ...

However, the new antibody design addresses these challenges. Its modular structure includes a bispecific antibody produced in ...

Cancer scientists say they have engineered a new type of super-strong antibody which could be used to boost the immune systems of patients fighting the disease. Experts from the University of ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims ...

Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 ...

Archon Biosciences’ antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington ...

Monoclonal antibody design begins with identifying antibodies that bind to a specific target. One way to do this is to isolate antibody producing B-cells from human blood samples.

Nxera Pharma, previously known as Sosei Heptares or the Sosei Group, has entered a collaboration and licensing agreement with Antiverse to design antibodies for G-protein coupled receptors (GPCRs ...